{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-091170","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2024-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.309928+00:00","generated_at":"2026-05-30T09:45:06.510940+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"INmune Bio to host Nov 7 webinar on EMACC cognitive tool for Alzheimer's trials","bullets":["Webinar on Nov 7, 2024 at 1 PM ET, titled \"Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials.\"","Poster on EMACC sensitivity and performance in Phase II Alzheimer's trial presented at CTAD2024.","Company is conducting a Phase II trial of XPro in early AD using EMACC and CDR-SB as endpoints.","No financial results, clinical data readouts, or material business changes disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-091170","json":"https://secwatch.observer/filing/0001213900-24-091170.json","markdown":"https://secwatch.observer/filing/0001213900-24-091170.md","text":"https://secwatch.observer/filing/0001213900-24-091170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024091170/0001213900-24-091170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024091170/ea0218711-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:45:06.510940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}